-
-
-
-
-
-
-
Vanda receives Japan orphan drug designation for GPP treatment
-
-
-
-
-
-
-
Vanda starts trial of NEREUS drug for GLP-1 side effects
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) call put ratio 4.2 calls to 1 put into announces FDA approval of Bysanti tablets
-
-
-
-
-
-
-
Increasing unusual option volume: EWC VNDA TKO XERS CORT ZSL BXSL OTLK PSQ CDZI
-
-
-
-
-
-
-
B.Riley Starts Vanda Pharmaceuticals (VNDA) at Buy
-
-
-
-
-
-
-
Vanda requests FDA commissioner review of generic Hetlioz approvals
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA): FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA
-
451,541 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

